{
  "docId": "019dd923-622c-750b-8b9a-101b5bfde4b8",
  "docSlug": "a70fecd99534",
  "documentTitle": "Berkeley Lights (BLI)",
  "authorId": "58_Scorpion_Capital",
  "authorName": "Scorpion Capital",
  "documentKindSlug": "research-note",
  "documentKindLabel": "Research note",
  "sourceTypeSlug": "short_seller",
  "sourceTypeLabel": "Short seller",
  "presentationDate": "2021-09-15 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.2941177,
  "pageNumber": 73,
  "pageCount": 158,
  "prevPage": 72,
  "nextPage": 74,
  "slideType": "testimonial",
  "function": "summarize",
  "density": "balanced",
  "nDataPoints": 1,
  "notes": "The slide uses a Q&A format to validate the thesis that the machine failed to scale due to reliability concerns.",
  "elementsJson": [
    "headline_text",
    "paragraph",
    "quote_block",
    "footnote"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622c-750b-8b9a-101b5bfde4b8/73",
  "deckHref": "/decks/019dd923-622c-750b-8b9a-101b5bfde4b8",
  "deckJsonHref": "/decks/019dd923-622c-750b-8b9a-101b5bfde4b8.json",
  "deckAnchorHref": "/decks/019dd923-622c-750b-8b9a-101b5bfde4b8#slide-73",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "NOVARTIS cell and gene therapy (cont’d): Came to view machine as too high-risk for operational use; other groups beyond cell and gene therapy, such as antibody discovery, evaluated the instrument and rejected it; reliability and stability issues led to machine being barely used, around 3-4 times a month.",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd953-2042-70a9-a1aa-4e6c06dda761",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.65,
        "w": 0.9,
        "x": 0.05,
        "y": 0.25
      },
      "kind": "list",
      "text": "Machine was used only 3 to 4 times a month. Novartis initially planned to wide use from discovery to manufacturing, where most of the ROI is, but it never panned out. Machine was too high-risk to use in actual operations.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "63808465-8caa-4d96-ad99-db49b77b0236",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "quote",
      "text": "This is not a scalable investment. The initial plan was to use it in this particular setting, and then widen use to other discovery programs, and then eventually make its way to manufacturing, which is where the biggest bang for the buck. If we start using this machine in a manufacturing setting, that's where the real big money is. It never panned out. — Novartis Expert",
      "attrs": null,
      "subkind": null,
      "toolName": "Authority citation",
      "toolSlug": "authority-citation",
      "confidence": null,
      "componentId": "019dd953-2042-70a9-a1aa-500db7014160",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.3,
        "x": 0.05,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "Source: Scorpion Capital consultation calls with experts",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "058526fa-700c-4d2e-b0ab-18c5b44e6a86",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.9,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "NOVARTIS cell and gene therapy (cont'd): Came to view machine as too high-risk for operational use; other groups beyond cell and gene therapy, such as antibody discovery, evaluated the instrument and rejected it; reliability and stability issues led to machine being barely used, around 3-4 times a month.",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d7742dd7-b067-4dff-aa43-c511ec3a4caa",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 75,
      "from": 17,
      "beatId": "dbc4e03f-819a-4342-92d6-d159c538f28f",
      "arcName": "Overcoming the Monster",
      "arcSlug": "overcoming-monster",
      "beatName": "Exposure of Contradictions",
      "beatSlug": null,
      "evidence": "The document exposes contradictions in Berkeley Lights' claims and actions, highlighting the company's struggles and poor market traction.",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    },
    {
      "to": 150,
      "from": 42,
      "beatId": "172d6e2f-be3f-4802-92e5-e7e412ccdabe",
      "arcName": "Overcoming the Monster",
      "arcSlug": "overcoming-monster",
      "beatName": "Testimonials from Customers and Former Employees",
      "beatSlug": null,
      "evidence": "The document presents testimonials from customers and former employees, providing first-hand accounts of the challenges and limitations of Berkeley Lights' product.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}